Academic Publications

Heller, N. H. & Barrett, F. S. (2024). Teaching a new dog old tricks: bringing rigor, grounding, and specificity to psychedelic neuropsychopharmacology. Neuropsychopharmacology. Published Online. August 26, 2024.

VanderZwaag, B., Garcia-Romeu, A., & Garcia-Barrera, M. A. (in press). Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery. Therapeutic Advances in Psychopharmacology, 14. Published Online. August 7, 2024

Yaden, D. B., Mathai, D., Bogenschutz, M., & Nichols, D. E. (2024). The pharmacology of hallucinogens. In: Miller et al. (Eds.). Principles of Addiction Medicine. American Society of Addiction Medicine.

Yaden, D. B., Nayak, S. M., Griffiths, R. R. (2024). Belief change and agnostic frames in psychedelic research and clinical contexts. In: C. Letheby (Ed.). Philosophy and the psychedelic renaissance. Oxford University Press, New York.

Hughes, M. E., & Garcia-Romeu, A. (2024). Ethnoracial inclusion in clinical trials of psychedelics: a systematic review. EClinicalMedicine, 74, 102711-102711.

DiRenzo, D., Barrett, F. S., Perin, J., Darrah, E., Christopher-Stine, L., & Griffiths, R. R. (2024). Impact of psilocybin on peripheral cytokine production. Psychedelic Medicine, 2(2).

DellaCrosse, M. A., Garcia-Romeu, A., & Davis, A. K. (2024). Seeing the forest for the trees: An ecological systems theory approach to addressing emergent issues in psychedelic-assisted therapy research. Journal of Psychedelic Studies. Published Online. June 5, 2024.

Cheung, K., Propes, C., Jacobs, E., Earp, B. D., & Yaden, D. B. (2024). Psychedelic group-based integration: Ethical assessment and initial recommendations. International Review of Psychiatry, 1–11.

Tiwari, P., Ehrenkranz, R., & Yaden, D. B. (2024). Psychiatric Applications of Psychedelics: Neurobiological Foundations for Treatments of Depression, Anxiety, and Obsessive-Compulsive Disorder. Advances in Psychiatry and Behavioral Health.

McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M., Celidwen, Y., Devenot, N., Gracias, S., Grob, C., Harvey, I., Kious, B., Marks, M., Mithoefer, M., Nielson, E., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Summergrad, P., Waters, B., Williams, M. T., & Yaden, D. B. (2024). Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Network Open, 7(6), e2414650.

Ehrenkranz, R., Agrawal, M., J. Kim Penberthy, & Yaden, D. B. (2024). Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder. International Review of Psychiatry, 1–12.

Nayak, S. M., White, S. H., Hilbert, S. N., Lowe, M. X., Jackson, H., Griffiths, R. R., Garcia-Romeu, A., & Yaden, D. B. (2024). Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study. Journal of Psychoactive Drugs, 1–10. Published Online. May 7, 2024.

Henningfield, J. E., Belouin, S. J., Yaden, D. B., Urrutia, J., Anderson, B. T., Berger, A., Grob, C. S., Labate, B. C., Maier, L. J., M Catherine Maternowska, Weichold, F., & Magar, V. (2024). In Memoriam: Roland R. Griffiths (July 19, 1946–October 16, 2023). Journal of Psychoactive Drugs, 1–2.

Jacobs, E., Earp, B. D., Appelbaum, P. S., Bruce, L., Cassidy, K., Celidwen, Y., Cheung, K., Clancy, S. K., Devenot, N., Evans, J., Lynch, H. F., Friesen, P., Garcia-Romeu, A., Gehani, N., Maloof, M., Marcus, O., Martin Moen, O., Mertens, M., Nayak, S. M., Noorani, T., … Yaden, D. B. (2024). The Hopkins-Oxford Psychedelics Ethics (HOPE) Working Group Consensus Statement. The American Journal of Bioethics, 24(7), 6–12.

Gordon, A. R., Carrithers, B. M., Pagni, B. A., Kettner, H., Alessia Marrocu, Nayak, S., Weiss, B. J., Carhart-Harris, R. L., Roberts, D. E., & Zeifman, R. J. (2024). The Effect of Psychedelics on Individuals with a Personality Disorder: Results from two Prospective Cohort Studies. Research Square.

Meling, D., Ehrenkranz, R., Nayak, S. M., Aicher, H. D., Funk, X., Van Elk, M., Graziosi, M., Bauer, P. R., Scheidegger, M., & Yaden, D. B. (2024). Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression. Psychoactives, 3(2), 215-234.

Graziosi, M., Rohde, J. S., Tiwari, P., Siev, J., & Yaden, D. B. (2024). Psychedelics, OCD and related disorders: A systematic review. Journal of Obsessive-Compulsive and Related Disorders, 41, 100873.

Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024). The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PLoS ONE, 19(3), e0300501.

Strickland, J. C., Garcia-Romeu, A., Johnson, M. W. (2024). The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item. Psychedelic Medicine, 2(1), 33-43.

Cheung, K., Earp, B. D., & Yaden, D. B. (2024). Valuing the Acute Subjective Experience. Perspectives in Biology and Medicine, 67(1), 155–165.

Sandbrink, J. D., Johnson, K., Gill, M., Yaden, D. B., Savulescu, J., Hannikainen, I. R., & Earp, B. D. (2024). Strong bipartisan support for controlled psilocybin use as treatment or enhancement in a representative sample of US Americans: Need for caution in public policy persists. AJOB Neuroscience, 15(2), 82–89.

Barnett, B. S., Anand, A., Dewey, E. N., Smith, D., Nayak, S. M., Bruckman, D., & Weleff, J. (2024). Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide’s Risk Profile More Favorably? Psychedelic Medicine.

Cheung, K., & Yaden, D. B. (2024). Commentary: On the need for metaphysics in psychedelic therapy and research. Frontiers in Psychology, 14, 1341566.

O’Donnell, K. C., Anderson, B. T., Barrett, F. S., Bogenschutz, M. P., Grob, C. S., Hendricks, P. S., Kelmendi, B., Nayak, S. M., Nicholas, C. R., Paleos, C. A., Stauffer, C. S., & Gukasyan, N. (2024). Misinterpretations and omissions: A critical response to Goodwin and colleagues’ commentary on psilocybin-assisted therapy. American Journal of Psychiatry, 181(1), 74–75.

Weiss, B., Roseman, L., Giribaldi, B., Nutt, D. J., Carhart-Harris R. L., Erritzoe, D. Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder. International Journal of Mental Health and Addiction, 1-36.

Marrocu, A., Kettner, H., Weiss, B., Zeifman, R. J., Erritzoe, D., Carhart-Harris, R. L. (2024). Psychiatric risks for worsened mental health after psychedelic use. Journal of Psychopharmacology, 38(3), 225-235.

Solaja, I., Haldane, K., Mason, N., Weiss, B., Xu, X., Xu, M., Nikolin, S., Jayasena, T., Millard, M., Brett, J., Bayes, A., Loo, C. K., Martin, D. M. (2024). Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition/creativity, emotional processing and personality. Neuroscience & Biobehavioral Reviews, 158, 105570.

James, E., Erritzoe, D., Benway, T., Joel, Z., Timmermann, C., Good, M., Agnorelli, C., Weiss, B. M., Barba, T., Campbell, G., Jones, M. B., Hughes, C., Topping, H., Boyce, M., Routledge, C. (2024). Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial. Frontiers in Psychiatry, 14, 1305796.

Szigeti, B., Weiss, B., Rosas, F. E., Erritzoe, D., Nutt, D., Carhart-Harris, R. (2024). Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychological Medicine, 1-8.

Yaden, D. B., Berghella, A. P., Hendricks, Yaden, M. E., Levine, M., Rohde, J. S., Nayak, S. M., Johnson, M. W., Garcia-Romeu, A. (2024). IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models. Pharmacological Research, 199, 106998.

O’Donnell, K. C., Anderson, B. T., Barrett, F. S., Bogenschutz, M. P., Grob, C. S., Hendricks, P. S., Kelmendi, B., Nayak, S. M., Nicholas, C. R., Paleos, C. A., Stauffer, C. S., & Gukasyan, N. (2024). Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues’ Commentary on Psilocybin-Assisted Therapy. American Journal of Psychiatry, 181(1), 74–75.

Devenot, N., Pace, B. A., Slot, J., & Davis, A. K. (2023). Psychedemia: Charting the future of interdisciplinary Psychedelic Studies: Introduction to the Special Issue. Journal of Psychedelic Studies, 7(S1), 1–5. Journal of Psychedelic Studies, 7(S1), 1-5.

Thrul, J., Kozak, Z., Carducci, M. A., Garcia-Romeu, A., & Yaden, D. B. (2023). Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer. Cancer, 130(7), 1028-1030.

Doss, M. K., Samaha, J., Barrett, F. S., Griffiths, R. R., de Wit, H., Gallo, D. A., & Koen, J. D. (2023). Unique effects of sedatives, dissociatives, psychedelics, stimulants, and cannabinoids on episodic memory: A review and reanalysis of acute drug effects on recollection, familiarity, and metamemory. Psychological Review, 131(2), 523–562..

Dworkin, R. H., McDermott, M. P., Nayak, S. M., & Strain, E. C. (2023). Reply to “Capturing Synergy Holistically in Psychedelic Clinical Trials.” Clinical Pharmacology & Therapeutics, 115(3), 401-402.

Weiss, B., Dinh-Williams, L.-A. L., Beller, N., Raugh, I. M., Strauss, G. P., & Campbell, W. K. (2023). Ayahuasca in the treatment of posttraumatic stress disorder: Mixed-methods case series evaluation in military combat veterans. Psychological Trauma: Theory, Research, Practice, and Policy.

Weiss, B., Sleep, C. E., Beller, N. M., Erritzoe, D., & Campbell, W. K. (2023). Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model. Journal of Psychedelic Studies, 7(3), 200-226.

Yaden, D. B., Berghella, A. P., Hendricks, P. S., Yaden, M. E., Levine, M., Rohde, J. S., Nayak, S., Johnson, M. W., & Garcia-Romeu, A. (2024). IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models. Pharmacological Research, 4, 106998.

van Elk, M., & Yaden, D. (2023). De-Siloing the Psychology of Religion and Psychedelic Science: Introduction to the Special Issue on Psychedelics and Mystical-type Experiences. The International Journal for the Psychology of Religion, 33(4), 255–258.

Wolinsky, D., Barrett, F. S., & Vandrey, R. (2023). The psychedelic effects of cannabis: A review of the literature. Journal of Psychopharmacology, 2024;38(1):49-55.

Graziosi, M., Singh, M., Nayak, S. M., & Yaden, D. B. (2023). Acute Subjective Effects of Psychedelics within and Beyond WEIRD Contexts. Journal of psychoactive drugs, 55(5), 558-569.

Mathai, D. S., Roberts, D. E., Nayak, S. M., Sepeda, N. D., Lehrner, A., Johnson, M., Lowe, M. X., Jackson, H., & Garcia-Romeu, A. (2023). Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use. PsyArXiv.

Dworkin, R. H., McDermott, M. P., Nayak, S. M., & Strain, E. C. (2023). Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?. Clinical Pharmacology & Therapeutics. Clinical Pharmacology & Therapeutics.

Urrutia, J., Anderson, B. T., Belouin, S. J., Berger, A., Griffiths, R. R., Grob, C. S., Henningfield, J. E., Labate, B. C., Maier, L. J., Maternowska, M. C., Weichold, F., Yaden, D. B., & Magar, V. (2023). Psychedelic Science, Contemplative Practices, and Indigenous and Other Traditional Knowledge Systems: Towards Integrative Community-Based Approaches in Global Health.  Journal of Psychoactive Drugs, 55(5), 523–538.

Nayak, S. M., Jackson, H., Sepeda, N. D., Mathai, D. S., So, S., Yaffe, A., Zaki, H., Brasher, T. J., Lowe, M. X., Jolly, D. R. P., Barrett, F. S., Griffiths, R. R., Strickland, J. C., Johnson, M. W., Jackson, H., & Garcia-Romeu, A. (2023). Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey. Frontiers in Psychiatry, 14, 1199642.

Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., Mletzko, T., Nicholas, C. R., Hutson, P. R., Tarpley, G., Utzinger, M., Lenoch, K., Warchol, K., Gapasin, T., Davis, M. C., Nelson-Douthit, C., Wilson, S., Brown, C., Linton, W., Ross, S., & Griffiths, R. R. (2023). Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA, 330(9), 843-853.

Xin, Y., Armstrong, S. B., Averill, L. A., Sepeda, N., & Davis, A. K. (2023). Predictors of psychedelic treatment outcomes among special operations forces veterans. Psychology of Consciousness: Theory, Research, and Practice.

Mathai, D. S., Hilbert, S., Sepeda, N. D., Strickland, J. C., Griffiths, R. R., & Garcia-Romeu, A. (2023). Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers. Psychedelic Medicine.

Medeiros, G. C., Matheson, M., Demo, I., Reid, M. J., Matheson, S., Twose, C., Smith, G. S., Gould, T. D., Zarate, C. A., Barrett, F. S., & Goes, F. S. (2023). Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies. The Lancet Psychiatry.

Armstrong, S. B., Levin, A. W., Xin, Y., Horan, J. C., Luoma, J., Nagib, P., Pilecki, B., & Davis, A. K. (2023). Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States. Journal of Psychedelic Studies, 7(S1), 61-67.

Steinberg, M., Rosenberg, P. & Garcia-Romeu, A. (2023). The Potential for Psychedelics to Improve Coping Skills and Resilience in Persons With Newly Diagnosed Mild Cognitive Impairment or Early Alzheimer’s Disease. Current Geriatric Reports, 12, 149–155 (2023).

Simonsson, O., Carlbring, P., Carhart-Harris, R., Davis, A. K., Nutt, D. J., Griffiths, R. R., Erritzoe D., & Goldberg, S. B. (2023). Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: a systematic review and individual participant data meta-analysis. Psychiatry Research.

O'Donnell, K., Roberts, D., Ching, T., Glick, G., Goldway, N., Gukasyan, N., Hokansen, J., Kelmendi, B., Ross, S., Yaden, M. & Pittenger, C. (2023). Letter to the Editor: What Is in a Name? The Many Meanings of “Psychedelic”. Psychedelic Medicine.

Davis, A. K., Timmermann, C., Ortiz Bernal, A. M., Lancelotta, R., Nayak, S., Sepeda, N. D., Nikolaidis, A., & Griffiths, R. R. (2023). Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences. Journal of psychoactive drugs, 1-11.

Bonnieux, J., VanderZwaag, B. & Garcia-Romeu, A. & Garcia-Barrera, M. (2023). Psilocybin’s effects on cognition and creativity: A scoping review. Journal of Psychopharmacology, 2023;37(7):635-648.

Davis, A. K., Xin, Y., Sepeda, N.D., & Averill, L. A. (2023). Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico. The American Journal of Drug and Alcohol Abuse, 49(5), 587–596.

Doss, M. K., de Wit, H., & Gallo, D. A. (2023). The acute effects of psychoactive drugs on emotional episodic memory encoding, consolidation, and retrieval: A comprehensive review. Neuroscience and Biobehavioral Reviews, 150, 105188.

Gaddis, A., Lidstone, D. E., Nebel, M. B., Griffiths, R. R., Mostofsky, S. H., Mejia, A. F., & Barrett, F. S. (2023). Corrigendum to 'Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity' NeuroImage, 274, 120130.

Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B. (2023). Psychedelics, Meaningfulness, and the "Proper Scope" of Medicine: Continuing the Conversation. Cambridge Quarterly of Healthcare Ethics, 1-7.

Tiwari, P., Berghella, A., & Sayali, C., Doss, M., Barrett, F. S., & Yaden, D. B. (2023). Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics. Psychedelic Medicine, 1, 74-86.

Haeny, A. M., Lopez, J., Colon-Grigas, P., Crouch, M., Davis, A. K., Williams, M. T. (2023).  Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among people with racial and ethnic minoritized identities in the United States and Canada. Journal of Substance Use and Addiction Treatment, 149:209035.

Gukasyan, N., Griffiths, R.R., Yaden, D.B., Antoine, D.G., Nayak, S.M. (2023) Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. Journal of Psychopharmacology, 2023;37(7):707-716.

Nayak S. M., Bradley M. K., Kleykamp B. A., Strain, E. C., Dworkin, R. H., Johnson, M. W. (2023). Control conditions in randomized trials of psychedelics: an ACTTION systematic review. Journal Clinical Psychiatry. 2023;84(3):22r14518.

Northoff, G., Klar, P., Bein, M. & Safron, A. (2023). As without, so within: How the brain’s temporospatial alignment to the environment shapes consciousness. Interface Focus. 13(3), 20220076.

Cotten, S. W., Strathmann, F. G., Barrett, F. S., Labay, L., Mullally, J., Sherwood, A. M., & Wiegand, F. (2023). Psychedelics for Medicinal Use: How Will This Alter the Collective Laboratory Consciousness?. Clinical Chemistry, 69(4), 319–326.

Christov-Moore, L., Jinich-Diamant, A., Safron, A., Lynch, C., & Reggente, N. (2023). Cognitive Science Below the Neck: Toward an Integrative Account of Consciousness in the Body. Cognitive Science, 47(3), e13264. 

Jacobs, E., Yaden, D., & Earp, B. D. (2023). Towards a Broader Psychedelic Bioethics. AJOB Neuroscience, 14(2), 126–129.

Nikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K. (2023). Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. Journal of Affective Disorders. 324, 239–249.

Yaden, D.B. & van Elk, M. (2023). Cultural dissonance and consonance in mystical-type experiences: commentary on “Finding consonance: an integrative neurocognitive model of human relationships with supernatural agents.” Religion, Brain & Behavior. 14(1), 58–61.

Nayak, S. M., Bari, B. A., Yaden, D. B., Spriggs, M. J., Rosas, F. E., Peill, J. M., Giribaldi, B., Erritzoe, D., Nutt, D. J. & Carhart-Harris, R. (2023). A Bayesian reanalysis of a trial of psilocybin versus escitalopram for depression. Psychedelic Medicine. 18-26.

Sayali, C. & Barrett, F. S. (2023). The costs and benefits of psychedelics on cognition and mood. Neuron, 111(5), 614–630.

Devenot, N., Seale-Feldman, A., Smith, E., Noorani, T., Garcia-Romeu, A., & Johnson, M. W. (2023). Psychedelic Identity Shift: A Critical Approach to Set And Setting. Kennedy Institute of Ethics Journal. 32(4), 359-399.

Mathai, D. S., Nayak, S. M., Yaden, D. B., & Garcia-Romeu, A. (2023). Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. Psychopharmacology. 240, 827–836.

Armstrong, S. B., Xin, Y., Sepeda, N. D., Polanco, M., Averill, L. A., Davis, A. K. (2023). Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans. Military Psychology, 36(2), 184–191.

Nautiyal, K. M., Yaden, D. B. (2023). Does the trip matter? Investigating the role of the subjective effects of psychedelics in persisting therapeutic effects. Neuropsychopharmacology. 48, 215–216 .

Beckman, M., Poulsen, S., Doss, M. K., & Stenbæk, D. S. (2023). Editorial: The psychotherapeutic framing of psychedelic drug administration. Frontiers in Psychology, 14.

Gukasyan, N. & Narayan, S.K. (2023). Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series. Journal of Psychoactive Drugs, 56(1), 50–55.

Nayak, S. M., Singh, M., Yaden D. B., & Griffiths R. R. (2023). Belief changes associated with psychedelic use. Journal of Psychopharmacology, 2023;37(1):80-92.

Kiluk, B. D., Kleykamp, B. A., Comer, S. D., Griffiths, R. R., Huhn, A. S., Johnson, M. W., Kampman, K. M., Pravetoni, M., Preston, K. L., Vandrey, R., Bergeria, C. L., Bogenschutz, M. P., Brown, R. T., Dunn, K. E., Dworkin, R. H., Finan, P. H., Hendricks, P. S., Houtsmuller, E. J., Kosten, T. R.,… Strain, E.C. (2023). Clinical trial design challenges and opportunities for emerging treatments for Opioid Use Disorder: a review. JAMA Psychiatry. 2023;80(1):84–92.

Gukasyan, N. (2023). On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression. Med, 4(1), 8–9.

Ortiz Bernal, A. M., Raison, C. L., Lancelotta, R. L., & Davis, A. K. (2022). Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon's predictors and its emotional valence. Frontiers in Psychiatry, 13, 1049643.

Yaden, D. B., Earp, B. D., & Griffiths, R. R. (2022). Ethical issues regarding nonsubjective psychedelics as standard of care. Cambridge Quarterly of Healthcare Ethics, 31(4), 464-471.

Safron, A. (2022). Integrated world modeling theory expanded: Implications for the future of consciousness. Frontiers in Computational Neuroscience, 16.

Gukasyan, N., Schreyer, C. C., Griffiths, R. R., & Guarda, A. S. (2022). Psychedelic-assisted therapy for people with eating disorders. Current Psychiatry Reports. 24, 767–775.

Henningfield, J. E., Coe, M. A., Griffiths, R. R., Belouin, S. J., Berger, A., Coker, A. R., Comer, S. D., Heal, D. J., Hendricks, P. S., Nichols, C. D., Sapienza, F., Vocci, F. J., & Zia, F. Z. (2022). Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacology, 218, 109220.

Hendricks, P., Nichols, C., Cunningham, K, Geyer, M., Griffiths, R, Nichols, D. (2022). Past, present, and future of psychedelics: A Psychedelic Medicine roundtable discussion. Psychedelic Medicine.

Gaddis, A., Lidstone, D. E., Nebel, M., Griffiths, R. R., Mostofsky, S. H., Mejia, A., & Barrett, F. S. (2022). Psilocybin induces spatially constrained alterations in thalamic functional organization and connectivity. NeuroImage, 260, 119434.

Levin, A., Nagib, P. B., Deiparine, S., Gao, T., Mitchell, J., & Davis, A. K. (2022). Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States. The International Journal on Drug Policy, 108, 103816.

Madden, M. B., Stewart, B. W., White, M. G., Krimmel, S. R., Qadir, H., Barrett, F. S., Seminowicz, D. A., & Mathur, B. N. (2022). A role for the claustrum in cognitive control. Trends in Cognitive Sciences, 26(12), 1133-1152.

Clifton, J. M., Belcher, A. M., Greenblatt, A. D., Welsh, C. M., Cole, T. O., & Davis, A. K. (2022). Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder, Journal of Psychedelic Studies, 6(2), 80-87.

Ross, S., Agrawal, M., Griffiths, R. R., Grob, C., Berger, A., & Henningfield, J. E. (2022). Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care. Neuropharmacology, 216, 109174.

van Elk, M. & Yaden, D. B. (2022). Pharmacological, Neural, and Psychological Mechanisms underlying Psychedelics: A Critical Review. Neuroscience & Biobehavioral Reviews, 143, 104793.

Luoma, J. B., Pilecki, B., Davis, A. K. & Smith, S. M. (2022) Predictors of attitudes toward psychedelics among psychologists in the USA, Drugs: Education, Prevention and Policy, 30(6), 543–549.

Barrett, F. S. (2022). Comparative pharmacology and circuit-level models of the effects of psychedelic drugs on the human brain. Biological Psychiatry Cognitive Neuroscience and Neuroimaging, 7(9), 849-851.

Yaden, D. B., Potash, J. B., & Griffiths, R. R. (2022). Preparing for the bursting of the psychedelic hype bubble. JAMA Psychiatry, 79(10), 943–944.

Sweeney, M. M., Nayak, S., Hurwitz, E. S., Mitchell, L. N., Swift, T. C., & Griffiths, R. R. (2022). Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying. PLoS ONE 17(8), e0271926.

de la Salle, S., Gran-Ruaz, S., Davis, D. D., Davis, A. K., & Williams, M. T. (2022). Acute and enduring effects of naturalistic psychedelic use among Indigenous peoples in Canada and the United States. Canadian Psychology / Psychologie canadienne, 63(4), 589–607.

Doss, M. K., Barrett, F. S., & Corlett, P. R. (2022). Skepticism about recent evidence that psilocybin "Liberates" depressed minds. ACS Chemical Neuroscience, 13(17), 2540–2543.

Mathai, D. & Yaden, D. B. & O’Donnell, K. (2022). The conundrum of therapeutic intoxication. The British Journal of Psychiatry, 221, 496-497.

Mathai, D. S., Lee, S. M., Mora, V., O’Donnell, K. C., Garcia-Romeu, A., & Storch, E. A. (2022). Mapping consent practices for outpatient psychiatric use of ketamine. Journal of Affective Disorders, 312, 113-121.

Ortiz, C. E., Dourron, H. M., Sweat, N. W., Garcia-Romeu, A., MacCarthy, S., Anderson, B. T., & Hendricks, P. S. (2022). Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. Neuropharmacology, 214, 109127.

Boehnke, K. F., Davis, A. K., & McAfee, J. (2022). Applying lessons from cannabis to the psychedelic highway: Buckle up and build infrastructure. JAMA Health Forum, 3(6), e221618.

McCulloch, D. E., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., Mason, N. L., Müller, F., & Fisher, P. M. (2022). Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. Neuroscience and biobehavioral reviews, 138, 104689.

Reckweg, J. T., Uthaug, M. V., Szabo, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022). The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). Journal of Neurochemistry, 162(1), 128-146.

Lawrence, B. W., Carhart-Harris, R., Griffiths, R. R., & Timmermann, C. (2022). Phenomenology and content of the inhaled N,N-dimethyltryptamine (N,N-DMT) experience. Scientific Reports, 12, 8562.

Yaden, D. B., Earp, D., Graziosi, M., Friedman-Wheeler, D., Luoma, J. B., & Johnson, M. W. (2022). Psychedelics and psychotherapy: cognitive-behavioral approaches as default. Frontiers in Psychology, 13, 873279.

Frymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022). The psychedelic integration scales: Tools for measuring psychedelic integration behaviors and experiences. Frontiers in Psychology, 13, 863247.

Bradberry, M. M., Gukasyan, N., Raison, C. L. (2022). Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies. JAMA Psychiatry, 79(6), 525-527.

Nayak, S. M., & Griffiths, R. R. (2022). A single belief-changing psychedelic experience is associated with increased attribution of consciousness to living and non-living entities. Frontiers in Psychology, 13, 852248.

Mathai, D. S., Mora, V., & Garcia-Romeu, A. (2022). Toward synergies of ketamine and psychotherapy. Frontiers in Psychology, 13, 868103.

Davis, A. K., Aterberry, B. J., Xin, Y., Agin-Liebes, G., Schwarting, C., & Williams, M. T. (2022). Race, ethnic, and sex differences in prevalence of and trends in hallucinogen consumption among lifetime users in the United States between 2015 and 2019. Frontiers in Epidemiology, 2, 876706.

Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151–158.

Golden, T.L., Magsamen, M., Sandu, C.C., Roebuck, G.M., Shi, K.M., & Barrett, F.S. (2022). Effects of setting on psychedelic experiences, therapies, and outcomes: A rapid scoping review of the literature. In: Barrett, F.S., Preller, K.H. (Eds.). Disruptive Psychopharmacology. Current Topics in Behavioral Neurosciences, vol 56. Springer, Cham.

Safron, A., & Sheikhbahaee, Z. (2022, February). Dream to Explore: 5-HT2a as Adaptive Temperature Parameter for Sophisticated Affective Inference. In: M. Kamp, et al. (Eds.). Machine Learning and Principles and Practice of Knowledge Discovery in Databases (pp. 799–809). Springer International Publishing.

Doss, M. K., Madden, M. B., Gaddis, A., Nebel, M., Griffiths, R. R., Mathur, B. N., & Barrett, F. S. (2022). Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain, 145(2), 441-456.

Mangini, P., Averill, L. A., & Davis, A. K. (2022). Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans. Journal of Psychedelic Studies, 5(3), 149-155.

Safron, A, Klimaj, V, Hipólito, I. (2022). On the importance of being flexible: Dynamic brain networks and their potential functional significances. Frontiers in Systems Neuroscience.

Barrett, F. S., Zhou, Y., Carbonaro, T. M., Roberts, J. M., Smith, G. S., Griffiths, R. R., & Wong, D. F. (2022). Human cortical serotonin 2A receptor occupancy by psilocybin measured using [11C]MDL 100,907 dynamic PET and a resting-state fMRI-based brain parcellation. Frontiers in Neuroergonomics, 2, 784576.

Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D., Dolan, S. B., Lancelotta, R., Timmermann, C., Ramaekers, J. G. (2022). The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of Psychopharmacology, 36(3), 309-320.

Zeifman, R. J., Yu, D., Singhal, N., Wang, G., Nayak, S. M., Weissman, C. R. (2022). Decreases in suicidality following psychedelic therapy: A meta-analysis of individual patient data across clinical trials. The Journal of Clinical Psychiatry, 83(2), 39235.

Ching, T. H. W., Davis, A. K., Xin, Y., & Williams, M. T. (2022). Effects of psychedelic use on racial trauma symptoms and ethnic identity among Asians in North America. Journal of Psychoactive Drugs, 55(1), 19–29.

Glynos, N. G., Pierce, J., Davis, A. K., McAfee, J., & Boehnke, K. F. (2022). Knowledge, perceptions, and use of psychedelics among individuals with fibromyalgia. Journal of Psychoactive Drugs, 55(1), 73–84

Yaden, D. B., Nayak, S. M., Gukasyan, N., Anderson, B. T., & Griffiths, R. R. (2022). The potential of psychedelics for end of life and palliative care. Current Topics in Behavioral Neurosciences. 56, 169–184.

Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., & Barrett, F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry, 11, 574.

Agin-Liebes, G., & Davis, A. K. (2021). Psilocybin for treatment of depression: a promising new pharmacotherapy approach. In: Barrett, F.S., Preller, K.H. (Eds.). Disruptive Psychopharmacology. Current Topics in Behavioral Neurosciences, vol 56. Springer, Cham.

Ciaunica, A., Safron, A. & Delafield-Butt, J. (2021). Back to square one: the bodily roots of conscious experiences in early life. Neuroscience of Consciousness, 7(2), 1–10.

Garcia-Romeu, A., Darcy, S., Jackson, H., White, T., Rosenberg, P. (2021). Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms. In: Barrett, F.S., Preller, K.H. (Eds.). Disruptive Psychopharmacology. Current Topics in Behavioral Neurosciences, vol 56. Springer, Cham.

Mathai, D.S., McCathern, A.G., Guzick, A.G., Schneider, S.C., Weinzimmer, S.A., Cepeda, S.L., Garcia-Romeu, A., & Storch, E.A. (2021). Parental attitudes toward use of ketamine in adolescent mood disorders and suicidality. Journal of Child and Adolescent Psychopharmacology, 31(8), 553-561.

Davis, A.K., Mangini, P., & Xin, Y. (2021). Ketamine-assisted psychotherapy for trauma-exposed patients in an outpatient setting: A clinical chart review study. Journal of Psychedelic Studies, 5(2), 94-102.

George, D.R., Hanson, R., Wilkinson, D., & Garcia-Romeu, A. (2021). Ancient roots of today’s emerging renaissance in psychedelic medicine. Culture, Medicine, and Psychiatry, 46, 890–903.

Davis, A. K., Agin-Liebes, G., España, M., Pilecki, B., & Luoma, J. B. (2021). Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. Journal of Psychoactive Drugs, 54(4), 309–318.

Nayak, S. M., Gukasyan, N., Barrett, F. S., Erowid, E., Erowid, F., Griffiths, R. R. (2021). Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry, 54(05), 240-245.

Davis, A. K., Xin, Y., Sepeda, N. D., Garcia-Romeu, A., & Williams, M. T. (2021). Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chronic Stress, 5, 1-10.

Yaden, Y. B., Berghella, A. P., Regier, P. S., Garcia-Romeu, A., Johnson, M. W., & Hendricks, P. S. (2021). Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. International Journal of Drug Policy, 98, 103380.

Yaden, Y. B., Johnson, M. W., Griffiths, R. R., Doss, M., Garcia-Romeu, A., Nayak, S., Gukasyan, N., Mathur, B. N., & Barrett, F. S. (2021). Psychedelics and consciousness: Distinctions, demarcations, and opportunities. International Journal of Neuropsychopharmacology, 24(8), 615–623.

Safron, A. & DeYoung, C. G. (2020). Integrating cybernetic big five theory with the free energy principle: a new strategy for modeling personalities as complex systems. 18, 617-649.

Safron, A. (2021). The radically embodied conscious cybernetic bayesian brain: from free energy to free will and back again. Entropy, 23(6), 783.

Cox, D. J., Garcia-Romeu, A., & Johnson, M. W. (2021). Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives. The American Journal of Drug and Alcohol Abuse, 47(4), 444-454.

Çatal, O., Verbelen, T., Van de Maele, T., & Dhoedt, B., & Safron, A. (2021). Robot navigation as hierarchical active inference. Neural Networks, 142, 192-204.

Thrul, J., & Garcia-Romeu, A. (2021). Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment. Drugs: Education, Prevention and Policy, 28(3), 211-214.

Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021). Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacology & Translational Science, 4(2), 543–552.

Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. M., & Davoli, C. C. (2021). Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharmacology & Translational Science, 4(2), 424–435.

Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R. (2021). Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. Journal of Psychopharmacology, 35(4), 353-361.

Lawrence, D. W., Sharma, B., Griffiths, R. R., Carhart-Harris, R. (2021). Trends in the Top-Cited Articles on Classic Psychedelics. Journal of Psychoactive Drugs. 53(4), 617-649.

Gukasyan, N. & Nayak, S. (2021). Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy. Transcultural Psychiatry.

Davis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021). Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. Journal of Psychopharmacology, 35(4), 437-446.

Strickland, J. C., Garcia-Romeu, A., & Johnson, M. W. (2021). Set and setting: a randomized study of different musical genres in supporting psychedelic therapy. ACS Pharmacology & Translational Science, 4(2), 472-478.

Johnson, M. W. (2021). Consciousness, religion, and gurus: pitfalls of psychedelic medicine. ACS Pharmacology & Translational Science, 4(2), 578-581.

Yaden, D. B., & Griffiths, R. R. (2021). The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science, 4(2), 568-572.

Williams, M. T., Davis, A. K., Xin, Y., Sepeda, N.D., Grigas, P. C., Sinnott, S., & Haeny, A. M. (2021). People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs: Education, Prevention and Policy, 28(3), 215-226.

Nayak, S., & Johnson, M. W. (2021). Psychedelics and psychotherapy. Pharmacopsychiatry, 54(04), 167-175.

Yaden, D. B., Yaden, M., & Griffiths, R. R. (2021). Psychedelics in Psychiatry—Keeping the Renaissance From Going Off the Rails. JAMA Psychiatry, 78(5), 469-470.

Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy for major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481-489.

Doss, M. K., May, D. G., Johnson, M. W., Clifton, J. M., Hedrick, S. L., Prisinzano, T. E., Griffiths, R. R., & Barrett, F. S. (2020). The acute effects of the atypical dissociative hallucinogen Salvinorin A on functional connectivity in the human brain. Scientific Reports, 10(1), 16392.

Barrett, F. S., Krimmel, S. R., Griffiths, R. R., Seminowicz, D. A., & Mathur, B. N. (2020). Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage, 218:116980.

Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T. (2020). Psychedelic treatment for trauma-related psychological and cognitive impairment among US Special Operations Forces Veterans. Chronic Stress, 4, 1-11.

Luoma, J. B., Chwyl, C., Bathje, G. J., Davis, A. K., & Lancelotta, R. (2020). A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. Journal of Psychoactive Drugs, 52(4), 289-299.

Safron, A. (2021). World Models and the Physical Substrates of Consciousness: Hidden Sources of the Stream of Experience? Journal of Consciousness Studies, 28(11-12), 210-221.

Müller, F., Johnson, M. W., & Borgwardt, S. (2020). Editorial: Hallucinogens and Entactogens: Establishing a New Class of Psychotherapeutic Drugs? Frontiers in Psychiatry, 11, Article 497.

Davis, A. K., Clifton, J. M., Weaver, E. G., Hurwitz, E. H., Johnson, M. W., & Griffiths, R. R. (2020). Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine (DMT): Phenomenology, interpretation, and enduring effects. Journal of Psychopharmacology, 34(9), 1008-1020.

Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R. (2020). Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology, 237, 2293–2304.

Dolan, S. B., & Johnson, M. W. (2020). The drug purity discounting task: Ecstasy use likelihood is reduced by probabilistic impurity according to harmfulness of adulterants. Drug and Alcohol Dependence, 208, 107772.

Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C, & Davis, A. K. (2020). Long-term effect of psychedelic drugs: A systematic review. Neuroscience & Biobehavioral Reviews, 113, 179-189.

Lancelotta, R, & Davis, A. K. (2020). Use of benefit enhancement strategies among 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) users: associations with mystical, challenging, and enduring effects. Journal of Psychoactive Drugs, 52(3), 273-281.

Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports, 10(1), 2214.

Uthaug, M. V., Lancelotta, R., Szabo, A., Davis, A. K., Riba, J., Ramaekers, J. G. (2020). Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology, 237(3), 773-785.

Garcia-Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2020). Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Frontiers Psychiatry, 10, 955.

Uthaug, M. V., Lancelotta, R., Ortiz Bernal, A.M., Davis, A.K., & Ramaekers, J.G. (2020). A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a natural setting. Journal of Psychedelic Studies, 4(2), 104-113.

Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & Davis, A. K. (2019). Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. Journal of Psychedelic Studies, 4(2), 114-122.

Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science, 15, 39-45.

Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33(9), 1088-1101.

Griffiths, R. R., Hurwitz, E. S., Davis, A. K., Johnson, M. W., & Jesse, R. (2019). Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE, 14(4), e0214377.

Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019). 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse, 1-16.

Barsuglia, J., Davis, A. K., Palmer, R., Lancelotta, R., Windham-Herman, A. M., Peterson, K., Polanco, M., Grant, R., & Griffiths, R. R. (2018). Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. Frontiers Psychology, 9, 2459.

Johnson, M. W., Hendricks, P. S., Barrett, F. S., Griffiths, R. R. (2018). Classic Psychedelics: An integrative review of epidemiology, mystical experience, brain network function, and therapeutics. Journal of Pharmacology & Therapeutics, 197, 83-102.

Johnson, M. W. (2018). Psychiatry might need some psychedelic therapy. International Review of Psychiatry. International Review of Psychiatry, 30(4), 285-290.

Garcia-Romeu, A., & Richards, W. A. (2018). Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry, 30(4), 291-316.

Barrett, F. S., Preller, K. H., & Kaelen, M. (2018). Psychedelics and music: neuroscience and therapeutic implications. International Review of Psychiatry, 30(4), 350-362.

Barrett, F. S., Carbonaro, T. M., Hurwitz, E., Johnson, M. W., & Griffiths, R. R. (2018). Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects of cognition. Psychopharmacology, 235(10), 2915-2927.

Davis, A. K., Renn, E., Windham-Herman, A. M., Polanco, M., & Barsuglia, J. P. (2018). A mixed-method analysis of persisting effects associated with positive outcomes following ibogaine detoxification. Journal of Psychoactive Drugs, 50(4), 287-297.

Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018). Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology, 32(7), 756-769.

Davis, A. K., Barsulglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. (2018). The epidemiology of 5-methyoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective uses, and reasons for consumption. Journal of Psychopharmacology, 32(7), 779-792.

Johnson, M. W., Griffiths, R. R., Hendricks, P. S., Henningfield, J.E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 1-24.

Barrett, F. S., Schlienz, J. N., Lembeck, N., Waqas, M., Vandrey, R. (2018). "Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs. Cannabis and Cannabinoid Research, 3(1), 85-93.

Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018). Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and difference in subjective experiences. Journal of Psychopharmacology, 235(2), 521-534.

Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology, 32(1), 49-69.

Johnson, M. J., Garcia-Romeu, A., Johnson, P. S. & Griffiths, R. R. (2017). An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology, 31(7), 841-850.

Garcia-Romeu, A., Griffiths, R.R., & , Johnson, M.W. (2017). Psychedelic-associated addiction remission: An online survey. Drug and Alcohol Dependence, 171, e69.

Davis, A. K., Barsuglia, J. P., Windham-Herman, A., Lynch, M., & Polanco, M. (2017). Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. Journal of Psychedelic Studies, 1(2), 65-73.

Saleemi, S., Pennybacker, S. J. Wooldridge, M., & Johnson, M. W. (2017). Who is ‘Molly’? MDMA adulterants by product name and the impact of harm-reduction services at raves. Journal of Psychopharmacology, 31(8), 1056-1060.

Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017). Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences, 117, 155-160.

Barrett, F. S, Johnson, M. W., & Griffiths, R. R. (2017). Psilocybin in long-term meditators: Effects on default mode network functional connectivity and retrospective ratings of quality experience. Drug and Alcohol Dependence, 171, e15-e16.

Barrett, F. S., Robbin, H., Smooke, D., Brown, J. L., & Griffiths, R. R. (2017). Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions. Frontiers in Psychology, 8, 1-12.

Barrett, F. S., Preller, K. H., Herdener, M., Janata, P., & Vollenweider, F. X. (2017). Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cerebral Cortex, 1-12.

Barrett F. S. & Griffiths, R. R. (2017). Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. In: AL Halberstadt, FX Vollenweider, and DE Nichols (Eds.). Behavioral Neurobiology of Psychedelic Drugs, Current Topics in Behaviorl Neurosciences, vol 36. Springer, Berlin, Heidelberg.

Johnson, M. W. & Griffiths, R. R. (2017). Potential therapeutic effects of psilocybin. Neurotherapeutics, 14(3), 734-740.

Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse, 43(1), 55-60.

Nichols, D. E., Johnson, M. W., & Nichols, C. D. (2017). Psychedelics as medicines: An emerging new paradigm. Clinical Pharmacology & Therapeutics, 101(2), 209-219.

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197.

Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016). Clinical applications of hallucinogens: A review. Experimental Clinical Psychopharmacology, 24(4), 229-268.

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J-M. S., Johnson, M. W. & Griffiths, R. R. (2016). The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 30(12), 1279-1295.

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12). 1268-1278.

Bogenschutz, M. P. & Johnson, M. W. (2016). Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 64, 250-258.

Maqueda, A. E., Valle, M., Addy, P. H., Antonijoan, R. M., Puntes, M., Coimbra, J., Ballester, M. R., Garrido, M., González, M., Claramunt, J., Barker, S., Lomnicka, I., Waguespack, M., Johnson, M. W., Griffiths, R. R., & Riba, J. (2016). Naltrexone but not ketanserin antagonizes the subjective, cardiovascular, and neuroendocrine effects of salvinorin-A in humans. International Journal of Neuropsychopharmacology, 19(7), 1-13.

Johnson, M. W., MacLean, K. A., Caspers, M. J., Prisinzano, Griffiths, R. R. (2016). Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. Journal of Psychopharmacology, 30(4), 323-329.

Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental session with psilocybin. Journal of Psychopharmacology. 29(11), 1182-1190.

Kaelen, M., Barrett, F. S., Roseman, R., Lorenz, R., Bolstridge, M., Curran, H. V., Feilding, A., Nutt, D. J, & Carhart-Harris, R. L. (2015). LSD enhances the emotional response to music. Journal of Psychopharmacology, 232(19), 3607-3614.

Sessa, B. & Johnson, M. W. (2015). Can psychedelic compounds play a part in drug dependence therapy? The British Journal of Psychiatry, 206(1), 1-3.

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. S., Johnson, M. W., MacLean, K. A., Jess, R., & Griffiths, R. R. (2015). The challenging experience questionnaire: Characterization of acute adverse reactions to psilocybin. Drug and Alcohol Dependence, 146, e218.

Carbonaro, T., Barrett, F., Bradstreet, M. P., Johnson, M. W., MacLean, K. A., Jess, R., & Griffiths, R. R. (2015). Survey study of challenging experiences after ingesting psilocybin mushrooms: Demographics and phenomenology. Drug and Alcohol Dependence, 146, e239-e240.

Hendricks, P. S., Johnson, M. W., & Griffiths, R. R. (2015). Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology 29(9), 1041-1043.

Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., &, Johnson, M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 29(3), 280-288.

Sessa, B., Johnson, M. W. From addiction to recovery using altered states of consciousness. In: Dickins R., ed. Psychedelic Press UK Volume 1; Cornwall, UK: Psychedelic Press; 2015;71-80.

Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2015). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews, 7(3), 157-164.

Tupper, K., Wood, E., Yensen, R., & Johnson, M. W. (2015). Psychedelic medicine: a re-emerging therapeutic paradigm. Canadian Medical Journal, 187(14), 1054-1059.

MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2015). Hallucinogens and club drugs. In: M. Galanter, H.D. Kleber, & K Brady (Eds.). The American Psychiatric Press Textbook of Substance Abuse Treatment (Fifth Edition) (pp 209-222),The American Psychiatric Press, Arlington, VA.

Hendricks, P., Clark, C., Johnson, M. W. (2014). Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Journal of Psychopharmacology, 28(1), 62-66.

Jesse, R. and Griffiths, R. R. (2014). Psilocybin research at Johns Hopkins: A 2014 report. In: J.H. Ellens (Ed.). Seeking the Sacred with Psychoactive Substances (Volume 2) (pp 29-43). Praeger, Santa Barbara, CA.

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 11, 983-992.

Caspers, M. J., Williams, T. D., Lovell, K. M. Lozama, A, Butelman, E. R., Kreek, M. J., Johnson, M., Griffiths, R., MacLean, K., & Prisinzano, T. E. (2013). LC-MS/MS quantification of salvinorin A from biological fluids. Analytical Methods, 5, 7042-7048.

MacLean, K. A., Johnson, M. W., Reissig, C. J., Prisinzano, T. E., & Griffiths, R. R. (2013). Dose-related effects of salvinorin A in humans: Dissociative, hallucinogenic and memory effects. Psychopharmacology, 226, 381-392.

Grob, C. S., Bossis, A. P. & Griffiths, R. R. (2013). Use of the Classic Hallucinogen Psilocybin for Treatment of Existential Distress Associated with Cancer. In: B.I. Carr and J.L.Steel (Eds.). Psychological Aspects of Cancer, (pp. 291-308) Springer Science and Business Media LLC, New York.

MacLean, K. A., Leoutsakos, J-M. S., Johnson, M. W., & Griffiths, R. R. (2012). Factor analysis of the Mystical Experience Questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion, 51(4), 721-737.

Johnson M. W. Hallucinogens. In: Rippe JM (Ed). Encyclopedia of Lifestyle Medicine and Health. vol 1. Thousand Oaks, CA: Sage Publications; 2012;529-30.

Reissig, C. J., Carter, L. P., Johnson, M. W., Mintzer, M. Z., Klinedinst, M. A., & Griffiths, R. R. (2012). High doses of dextromethorphan, an NMDA antagonist, produces effects similar to classic hallucinogens. Psychopharmacology, 223(1), 1-15. 

Johnson, M. W., Sewell, R. A, & Griffiths, R. R. (2012). Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug and Alcohol Dependence, 123, 132-140. 

MacLean, K. A., Johnson, M. W., & Griffiths, R. R.  (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 25(11), 1453-1461. 

Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects.  Psychopharmacology, 218(4), 649-665. 

Johnson, M. W. MacLean, K. A., Reissig, C. J., Prisinzano, T. E. & Griffiths, R. R. (2011). Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug and Alcohol Dependence, 115, 150-155.

Johnson, M. W. Salvia Divinorum. In: Kleiman M, Hawdon J, & Golson JG (Eds.). Encyclopedia of Drug Policy. vol 2. Thousand Oaks, CA: Sage Publications; 2011;709-11.

Griffiths, R. R. & Grob, C. S. (2010). Hallucinogens as medicine. Scientific American, 303, 77-79.

Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008).  Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603-620.

Griffiths, R. R., Johnson, M. W., Richards, W. A., McCann, U., & Richards, B. D. (2008).  Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621-632.

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R.  (2006). Psilocybin can occasion mystical experiences having substantial and sustained personal meaning and spiritual significance.  Psychopharmacology, 187, 268-283.